Index overviewEvent timeline

Akros SCHK HK-U.S. Biotech Index

Hong Kong and U.S. biotech leaders through Stock Connect.

Recent events

13 of 13
Aug 6, 2026

Q2 2026 earnings release on August 6, 2026, following a Q1 beat; medium importance estimated based on expected >=5% price impact, scheduled.

Aug 5, 2026
Eli Lilly and Co (LLY)
Earnings Release

Q2 2026 earnings release and conference call on 2026-08-05 scheduled. Low importance estimated as it is a routine scheduled announcement.

Aug 4, 2026
Merck and Co Inc (MRK)
Earnings Release

Merck & Co. is scheduled to release its Q2 2026 financial results on 2026-08-04. Earnings releases are high-impact events that can significantly influence stock price, estimated to have a high market impact (≥10%) scheduled.

Aug 4, 2026
Amgen Inc (AMGN)
Earnings Release

Amgen Q2 2026 earnings conference call on August 4, 2026, scheduled; medium impact estimated from updated financial outlook and guidance.

Aug 4, 2026
Pfizer Inc (PFE)
Earnings Release

Pfizer is scheduled to release its Q2 2026 earnings results before the market opens on August 4, 2026. Analysts forecast EPS of $0.68 and revenue of $14.45 billion, which is forecasted. Medium importance is estimated as earnings reports typically drive significant price volatility. The event is scheduled.

Jul 31, 2026
AbbVie Inc (ABBV)
Earnings Release

AbbVie's second-quarter 2026 financial results are scheduled to be announced on July 31, 2026, before the market opens; a 5% price impact is estimated based on historical earnings volatility, scheduled.

Jul 30, 2026

Q2 2026 earnings release scheduled. Analysts forecast EPS of $1.61. Expected to have a moderate impact as a key financial update; estimated.

Jul 29, 2026

FDA hearing deadline to address the proposal to withdraw marketing approval for Tavneos on July 29, 2026, scheduled; high impact estimated due to potential market exit and revenue loss.

Jul 16, 2026

Abbott is scheduled to report its Q2 2026 financial results on July 16, 2026, before the market opens. Options market data implies a potential 4.5% stock price move following the release. This is a future event, so importance is an estimate based on historical volatility. scheduled

Jul 15, 2026
Johnson & Johnson (JNJ)
Earnings Release

Johnson & Johnson is scheduled to release its Q2 2026 earnings results on July 15, 2026. Analysts forecast earnings of $2.86 per share on revenue of $25.06 billion. Medium importance is estimated based on historical price volatility following quarterly earnings reports, scheduled.

Jul 13, 2026

U.S. FDA accepted a New Drug Application for mezigdomide on 2026-07-13. Target action date (PDUFA) is May 13, 2027. This milestone is expected to have a moderate impact; expected.

Jul 10, 2026

The U.S. FDA approved KEYTRUDA in combination with Padcev for muscle-invasive bladder cancer on 2026-07-10. This major indication approval is estimated to have a medium market impact (≥5%) due to significant revenue potential expected.

Jul 10, 2026

The U.S. FDA approved the combination of Pfizer's PADCEV and Merck's Keytruda for muscle-invasive bladder cancer on July 10, 2026. Medium importance is estimated as this is the first platinum-free regimen for this indication, significantly expanding the market.